Immunogenicity caused by the use of nonhuman enzymes in antibody-directed enzyme prodrug therapy has limited its clinical application. To overcome this problem, we have developed a mutant human purine nucleoside phosphorylase, which, unlike the wild-type enzyme, accepts (deoxy)adenosine-based prodrugs as substrates. Among the different mutants of human purine nucleoside phosphorylase tested, a double mutant with amino acid substitutions E201Q:N243D (hDM) is the most efficient in cleaving (deoxy)adenosine-based prodrugs.
Introduction
Antibody-directed enzyme prodrug therapy (ADEPT) is a two-step cancer therapy. Firstly, an antibody-enzyme fusion is injected i.v. This fusion protein binds selectively to tumor antigens via its antibody component and localizes the enzyme to the tumor site (1 -4) . Secondly, after the unbound fraction is cleared from circulation, a nontoxic prodrug is systemically administered. The prodrug is converted to a potent cytotoxic drug by the antibodyenzyme fusion protein only at the tumor site. To date, only enzymes of nonhuman origin have been used in ADEPT, and despite promising results, their immunogenicity has restricted ADEPT to phase I clinical trials (5 -7) . However, if a human enzyme is used, the prodrug will be converted to a cytotoxic drug not only in the vicinity of the tumor but also at sites where the endogenous enzyme is present, causing systemic toxicity. One approach to overcoming this problem is to engineer a human enzyme with altered specificity, so that it can cleave a prodrug that is not cleaved by the naturally occurring enzyme. If the engineered human enzyme contains minimal changes in its structure and amino acid composition compared with the wild-type, it should be far less immunogenic than the currently used bacterial enzymes. Therefore, we have developed mutants of human purine nucleoside phosphorylase (hPNP) with altered substrate specificity for use in ADEPT.
hPNP, a ubiquitously expressed homotrimer, catalyzes the reversible phosphorolysis of 6-oxo purine nucleosides to the corresponding free purine base and ribose 1-phosphate but does not accept adenosine or adenosinebased prodrugs as substrates (8 -10) . In contrast, homohexameric Escherichia coli PNP (ePNP) efficiently converts adenosine-based prodrugs to adenine-containing drugs (11) , which can freely diffuse across cell membranes and are toxic to both dividing and nondividing cells (11 -15) , including the stromal cells that support tumor growth. Although these characteristics make ePNP an attractive candidate for ADEPT, the immunogenicity resulting from its bacterial origin limits the number of treatments that can be administered to cancer patients.
In the present study, we have used available crystallographic and enzyme-substrate studies (8 -10, 16 -22) to rationally design hPNP mutants that can cleave adenosinebased prodrugs not recognized by wild-type hPNP. In particular, a double mutant of hPNP, E201Q:N243D (hDM), which is fused to an anti-HER-2/neu peptide mimetic (AHNP; ref. 23) , is able to use (deoxy)adenosine-based prodrugs cladribine (Cl-dAdo), 2-fluoroadenosine (F-Ado), and 2-fluoro-2 ¶-deoxyadenosine (F-dAdo) as substrates, with the highest enzymatic efficiency seen with F-dAdo. hDM-AHNP localizes to HER-2/neu-expressing tumors and produces the toxic metabolite 2-fluoroadenine (F-Ade) by the phosphorolysis of F-dAdo. Generation of cytotoxic drug results in tumor cell apoptosis, making hDM-AHNP HER-2 -Fc was purchased from R&D Systems. Expression vectors for expression of TEV enzyme and ECD HER-2 were gifts from Dr. James Bowie (University of California-Los Angeles) and Dr. James Marks (University of California-San Francisco), respectively.
Cloning, expression, and purification of all proteins as well as binding assays using ELISA and flow cytometry are described in Supplementary Materials.
Determination of Kinetic Variables
For all enzyme reactions, the concentration of the enzyme was adjusted such that product formation was linear with respect to time. Unless stated, all enzyme reactions were done in triplicate in 96-well UV plates at 37jC in a final volume of 100 AL containing 125 mmol/L KH 2 PO 4 (pH 7.4) and 50 mmol/L HEPES. Following addition of substrates, a SpectraMax M5 spectrophotometer (Molecular Devices) was used to monitor the enzymatic reactions. The Michaelis-Menten kinetic variables were determined using Lineweaver-Burk plots of milliunits absorbance/min versus 1/concentration of substrate. Units of absorbance/min were converted to Amol/L/min using the extinction coefficient of either substrate consumed or product formed. V max was then converted to k cat .
Enzymatic Activity of PNPs with Adenosine and Guanosine Phosphorolysis of adenosine to adenine was followed in a continuous reaction containing xanthine oxidase by following the decrease in absorbance at 260 nm and the increase in absorbance at 301 nm. Adenosine was converted to adenine by PNP, and adenine was hydrolyzed to 2,8-dihydroxyadenine by xanthine oxidase. Both adenosine and adenine absorb at 260 nm, but 2,8-dihydroxyadenine absorbs at 301 nm. Molar extinction coefficients for adenosine and 2,8-dihydroxyadenine are 15,400 and 15,200 mol/L À1 cm À1 , respectively. Phosphorolysis of guanosine to guanine was followed by the decrease in absorbance at 257 nm using a molar extinction coefficient of 13,700 mol/L À1 cm À1 for guanosine.
Enzymatic Activity of PNPs with F-dAdo, Cl-dAdo, F-Ado, and Fluradabine Enzymatic cleavage of F-dAdo to F-Ade by PNPs was followed by a decrease in absorbance at 260 nm and a concurrent increase in absorbance at 280 nm. The conversion of Cl-dAdo and F-Ado to the corresponding products was followed in a coupled enzyme reaction containing xanthine oxidase with product formation monitored by a decrease in absorbance at 250 nm and a simultaneous increase in absorbance at 280 nm. The molar extinction coefficients of F-dAdo were determined to be 16,300 mol/L À1 cm À1 at 260 nm and 1,300 mol/L À1 cm
À1
at 280 nm. The molar extinction coefficients of Cl-dAdo and F-Ado were 10,000 and 12,000 mol/L À1 cm À1 at 250 nm, respectively. The ability of PNPs to cleave fluradabine was determined in a cell-based assay. First, the toxicity of fluradabine with CT26-HER-2/neu cells was determined. Following overnight growth of cells seeded at 5 Â 10 3 per well in a 96-well tissue culture plate, different concentrations of fluradabine alone or fluradabine and 2 Amol/L ePNP were added and the level of cell proliferation following incubation at 37jC for 72 h was determined by MTS assay (CellTiter 96 AQ ueous Nonradioactive Cell Proliferation Assay; Promega). At fluradabine concentrations exceeding 17 Amol/L, a dose-dependent decrease in cellular proliferation was observed, but at lower concentrations there was no inhibition of growth. When both fluradabine and ePNP were added, inhibition of cellular proliferation was observed at fluradabine concentrations of 8 Amol/L. Therefore, it was concluded that at concentrations below 17 Amol/L, fluradabine does not impair cell proliferation, but when present at 8 Amol/L it is converted to a cytotoxic product by ePNP that inhibits cell proliferation. Therefore, 8 Amol/L fluradabine was used with varying concentrations of ePNP and hPNPs to determine their enzymatic activity.
Surface Plasmon Resonance Analysis of the Interaction of hDM-AH-AHNP with ECD
HER-2
Binding of hDM-aH-AHNP to ECD HER-2 -Fc was studied using surface plasmon resonance on a BIAcore T100. ECD HER-2 -Fc was immobilized on the surface of a CM5 sensor chip following the standard amine coupling procedure based on the manufacturer's recommendation, achieving a surface density of 1,136 resonance units. The remaining active groups were blocked by injecting ethanolamine. The reference surface was generated following the same procedure but without protein. Following each binding cycle, the chip was regenerated using 0.2% (v/v) DMSO. hDM-aH-AHNP was injected at various concentrations at 20 AL/min. hPNP was injected under the same condition but only at a concentration equal to the highest concentration of hDM-aH-AHNP. Binding of hDM-aH-AHNP to the immobilized ligand was monitored in real-time by following association and dissociation phases on the experimental surface subtracted from the blank surface using BIAevaluation 3.0 software. Inhibition of cell growth (after 72 h) or induction of apoptosis (after 60 h) was determined by using a MTS assay or an Apoptosis Assay Kit (Molecular Probes/Invitrogen), respectively. Induction of DNA fragmentation due to apoptosis was examined 72 h post-addition of F-dAdo as described previously (25) . To block the interaction of AHNP in hDM-aH-AHNP with HER-2/neu expressed on the surface of CT26-HER-2/neu cells, different concentrations of soluble ECD HER-2 were incubated overnight at 4jC with hDM-aH-AHNP with mild shaking. The mix was then added to cells that had been seeded the night before and the assay was repeated as described above. For controls, F-dAdo, hDM-aH-AHNP, hPNP-GS-AHNP, hPNP-GS-AHNP plus F-dAdo, 6XHis-ePNP-GS-AHNP, or ECD HER-2 at the highest concentrations used was added to cells and the degree of cell proliferation was determined.
Molecular Modeling
The structure of hPNP with guanine (1ULB) was superimposed on the structure of ePNP in complex with F-dAdo (1PKE) and viewed by PyMol (26) . The two proteins share a conserved subunit fold; hence, their superimposition was possible.
Results

Substrate Specificity of Mutant hPNPs with Adenosine, F-dAdo, and Guanosine
To change the substrate specificity of hPNP so that it could cleave adenosine and adenosine-containing prodrugs, the single-mutant N243D (hSM) or the double-mutant, (E201Q:N243D, hDM) was introduced. Both mutants were fused to a S-tag at their NH 2 terminus to facilitate purification. Asn 243 in hPNP was recognized previously as the residue responsible for its substrate specificity (9, 10, 17, 18) . In contrast to hPNP, ePNP, which is highly active with adenosine and adenosine-based prodrugs, has Asp 204 that corresponds to Asn 243 of hPNP (11, 17, 27) . This Asp residue is conserved in all prokaryotic PNPs that phosphorolyse adenosine to adenine (17, 27 -29) . The S-tagged hSM (S-hSM) converted adenosine to adenine with a K m value of 501 Amol/L and an overall efficiency of 296 mol/L À1 s À1 (Table 1) . At the concentrations used, S-tagged wild-type hPNP (S-hPNP) did not show any activity with adenosine (Table 1 ). Importantly, it was shown previously that hSM was able to convert the cytotoxic drug 2-amino adenine to 2-amino-2 ¶-deoxyadenosine (10) . Given that the reaction is reversible, we hypothesized that hSM would also be able to catalyze the reaction in which an adenosine-based prodrug is converted to a toxic metabolite. Indeed, S-hSM used the relatively nontoxic deoxyadenosine-based prodrug, F-dAdo, as a substrate with a K m value of 3,735 Amol/L and an overall efficiency of 26 mol/L À1 s À1 (Table 2) . Therefore, hSM is capable of cleaving both adenosine and F-dAdo, with 100-fold lower efficiency for F-dAdo than for adenosine.
F-dAdo has a highly electronegative fluorine atom at the C2 position of the purine base. Based on the crystallographic studies, the double mutant of hPNP, hDM, is predicted to tolerate the fluorine substitution at the C2 position of F-dAdo better than hSM. Although S-hDM was 4-fold less efficient than S-hSM in phosphorolysis of adenosine (Table 1) , it was somewhat more effective than S-hSM in cleaving F-dAdo to a cytotoxic drug largely as a consequence of decreased K m ( Table 2) .
Conversion of F-dAdo to the cytotoxic drug, F-Ade, by S-hDM was verified using a cell-based assay in which CT26-HER-2/neu tumor cells were incubated with the enzyme in the presence or absence of F-dAdo. Cells proliferated normally when incubated with S-hPNP and F-dAdo; however, in the presence of S-hDM or S-tagged ePNP and F-dAdo, the toxic end product generated by either enzyme resulted in an inhibition of cell proliferation comparable with that observed in the presence of equal molar concentrations of F-Ade ( Supplementary Fig. S1 ). 1 Guanosine is a natural substrate of hPNP (21) . The wildtype enzyme catalyzes the reversible phosphorolysis of guanosine to guanine and ribose 1-phosphate with high efficiency. Although the mutant PNPs were capable of using guanosine as a substrate, they exhibited lower enzymatic efficiency than the hPNP. The S-hSM with a K m value of 133 Amol/L shows a 4-fold reduced affinity for phosphorolysis of guanosine and an overall reduction of 1,700-fold in the catalytic efficiency when compared with wild-type enzyme (Table 1) . Compared with S-hPNP, S-hDM showed an f15-fold reduced affinity for guanosine, indicating that the residue E201 plays an important role in phosphorolysis of guanosine (Table 1) .
In an attempt to further increase the activity of hDM with (deoxy)adenosine-based prodrugs, additional mutations were introduced within either the base-binding or the ribose-binding pocket of the enzyme (28) . However, none of the additional mutations resulted in enhanced enzyme activity with F-dAdo (Supplementary Table S1 ); 1 overall, hDM was the most efficient of the enzymes tested in cleaving the prodrug, F-dAdo.
hDM Is Active When Fused to AHNP To target the enzyme to the tumor site, hDM was fused at its COOH terminus to a 12-amino acid exocyclic peptide 1 Supplementary material for this article is available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/). called AHNP (23) . AHNP was designed based on the structure of the CDR-H3 loop of the anti-HER-2/neu recombinant monoclonal antibody 4D5 and binds specifically to the extracellular domain of HER-2/neu (23, 30 -32) with an affinity of 150 nmol/L (32). We hypothesized that, by fusing AHNP to the COOH terminus of hDM, active enzyme would be specifically targeted to HER-2/neuexpressing cells via the AHNP.
When AHNP was fused at the COOH terminus of hDM via a flexible Gly 3 SerGly linker (yielding hDM-GS-AHNP), its k cat using adenosine as substrate was comparable with S-hDM. However, an 8-fold increase in affinity of hDM-GS-AHNP for adenosine resulted in an 8-fold improvement in overall kinetic efficiency ( Table 1 ), suggesting that the NH 2 -terminal S-tag might interfere with enzyme-substrate binding. The NH 2 terminus of hPNP is in close proximity to the binding pocket of the enzyme and the NH 2 -terminal fusion may negatively influence enzyme activity through steric interference. ePNP and hPNP were also fused at their COOH terminus to AHNP via a Gly 3 SerGly linker, producing 6XHis-ePNP-GS-AHNP and hPNP-GS-AHNP, as positive and negative controls, respectively. When the enzymatic activities of the AHNP fusion proteins were compared using adenosine as substrate, hDM-GS-AHNP remained 140-fold less efficient than 6XHis-ePNP-GS-AHNP (Table 1) . At the concentration used, hPNP-GS-AHNP was not active (Table 1) . Importantly, hDM-GS-AHNP used F-dAdo with k cat values comparable with S-hDM, but with f7-fold lower K m , making hDM-GS-AHNP a more efficient enzyme (Table 2) . When compared with 6XHis-ePNP-GS-AHNP, hDM-GS-AHNP was f70-fold less active with F-dAdo as substrate (Table 2) .
When the flexible Gly 3 SerGly linker was replaced with a rigid a-helical linker (33, 34), hDM-aH-AHNP was found to be 2-fold more active using F-dAdo as substrate ( Table 2 ). The increased activity was possibly due to a better spatial separation that eliminated unfavorable interactions between AHNP and hDM.
AHNP Targets hDM to the Extracellular Domain of HER-2/neu
To show that AHNP in the fusion protein hDM-aH-AHNP specifically targets the enzyme to HER-2/neu, binding of hDM-aH-AHNP to ECD HER-2 -Fc was examined by surface plasmon resonance as described above. Analysis by global fitting using a 1:1 Langmuir model, with the binding of each AHNP to ECD HER-2 -Fc assumed to be independent of the others, yielded a K d of 430 nmol/L (Fig. 1A) , 3-fold higher than the published value for AHNP alone (150 nmol/L; ref. 32). Binding of hPNP at a concentration equal to the highest concentration of hDM-aH-AHNP to ECD HER-2 -Fc immobilized on the sensor chip was negligible (Fig. 1A) . In addition, biotinylated hDM-aH-AHNP Table 2 . Kinetic constants for engineered PNP fusion proteins for F-dAdo showed a dose-dependent binding to ECD HER-2 immobilized on microtiter plates, with half-maximum binding at f0.17 Amol/L (Fig. 1B) . Specific binding by hDMaH-AHNP greatly exceeded the nonspecific binding seen by biotinylated hPNP (Fig. 1B) .
Hexameric 6XHis-ePNP-GS-AHNP bound ECD HER-2 -Fc immobilized on the CM5 chip with an affinity of f2.3 nmol/L, a strong interaction owing to the slow offrate (f8.5 Â 10 À5 1/s; data not shown). Specific binding of 6XHis-ePNP-GS-AHNP to ECD HER-2 and to cells expressing HER-2/neu was also seen using ELISA and flow cytometry ( Supplementary Fig. S2 ). 1 
hDM-AH-AHNP Is Capable of Using Multiple Prodrugs as Substrate
In addition to F-dAdo, two other (deoxy)adenosine-based prodrugs, Cl-dAdo and F-Ado, were evaluated as substrates for hDM-aH-AHNP. F-Ado and Cl-dAdo are adenosine and deoxyadenosine analogue prodrugs, respectively, with Cl-dAdo currently being used to treat leukemia (35) . hDM-aH-AHNP was active with both Cl-dAdo and F-Ado as substrates, with K m values of 838 and 447 Amol/L, respectively (Table 3) . Although hDM-aH-AHNP had a 3-fold higher k cat value for F-Ado compared with F-dAdo, the overall kinetic efficiency of the enzyme was slightly higher for F-dAdo. 6XHis-ePNP-GS-AHNP had the highest enzyme efficiency with F-Ado followed by F-dAdo and Cl-dAdo (Tables 2 and 3) .
Enzymatic activity of hPNPs with fludarabine as substrate was tested by their ability to convert fludarabine to a cytotoxic drug that would inhibit cell proliferation. CT26-HER-2/neu cells grow normally in the presence of 8 Amol/L fludarabine, but when 6XHis-ePNP-GS-AHNP was also present, generation of toxic product due to enzymatic activity of ePNP resulted in 90% inhibition of cell growth. In contrast to ePNP, addition of hPNP mutants did not result in growth inhibition of either CT26-HER-2/ neu or CT26 cells, indicating that these mutant enzymes could not use fludarabine as substrate.
In vitro Cytotoxicity of F-dAdo in the Presence of Localized hDM-AH-AHNP or 6XHis-ePNP-GS-AHNP
To determine if AHNP association with HER-2/neu can specifically target the enzyme to HER-2/neu-expressing tumor cells, the fusion protein was added to CT26-HER-2/ neu or CT26 cells, unbound protein was washed away, and F-dAdo was added. If the fusion protein remained bound to the cells, the enzyme would catalyze phosphorolysis of F-dAdo to F-Ade, resulting in inhibition of cell proliferation. To determine the optimal prodrug concentration, different dilutions of F-dAdo were added to cells, and after 72 h, the degree of cell proliferation was determined by MTS assay. CT26-HER-2/neu or CT26 cells grow normally if F-dAdo was added at concentrations of V2 Amol/L (Fig. 2A) . In contrast, addition of 1.5 Amol/L F-Ade inhibited CT26-HER-2/neu or CT26 proliferation by at least 85% ( Fig. 2A) . Therefore, addition of 1.5 Amol/L F-dAdo will result in significant cytotoxicity only if it is converted to F-Ade by the enzymatic activity of PNP. Different concentrations of hDM-aH-AHNP or 6XHis-ePNP-GS-AHNP were added to cells and the unbound fraction was washed away followed by addition of F-dAdo at 1.5 Amol/L. This resulted in a dose-dependent inhibition of proliferation with CT26-HER-2/neu but not with CT26 ( Fig. 2B and C) . Cytotoxicity was seen only when fusion protein and F-dAdo were added, because addition of enzyme or prodrug alone (at the highest concentration) did not cause any cytotoxicity resulting in inhibition of cell proliferation (data not shown). Consistent with its greater enzyme activity, cytotoxicity was seen at lower concentrations of 6XHis-ePNP-GS-AHNP than hDM-aH-AHNP ( Fig. 2B and C) . Incubation of the hDM-aH-AHNP with soluble ECD HER-2 before addition to CT26-HER-2/neu cells inhibited the interaction of the fusion protein with HER-2/ neu expressed on the cell surface and restored cell proliferation to normal levels (Fig. 2D) .
hDM-aH-AHNP was also capable of associating with MCF-7-HER-2, a human breast cancer cell line that was transfected with full-length HER-2/neu cDNA to increase its expression of HER-2/neu. MCF-7-HER-2 cells proliferated normally in the presence F-dAdo or hDM-aH-AHNP alone (data not shown). However, the enzymatic activity of the hDM-aH-AHNP that remained bound to HER-2/neu expressed on MCF-7-HER-2 cells resulted in conversion of F-dAdo to F-Ade and inhibition of cell proliferation (Fig. 2B) . Inhibition of cellular proliferation as a result of conversion of F-dAdo to F-Ade was also seen with non-HER-2/ neu-expressing tumor cells if the cells were not washed after addition of hDM-aH-AHNP. Proliferation of 38C13 cells, a mouse B lymphoma cell line, was inhibited in a dose-dependent manner with different concentrations of hDM-aH-AHNP in the presence of 1 Amol/L F-dAdo ( Supplementary Fig. S3 ).
1 hDM-aH-AHNP at its highest concentration or 1 Amol/L F-dAdo alone had no affect on proliferation of 38C13 cells (data not shown).
Importantly, to determine if generation of cytotoxic drug due to hDM enzymatic activity causes only inhibition of cell proliferation or if it results in tumor cell death, CT26-HER-2/neu cells were incubated with hDM-aH-AHNP in the presence or absence of F-dAdo. Cells were then examined for DNA fragmentation or stained with propidium iodide and Annexin V and examined by flow cytometry 72 or 60 h post-addition of F-dAdo, respectively. Table 3 . Comparison of kinetic constants for adenosine-based prodrugs of hPNP-GS-AHNP, hDM-AH-AHNP, and 6XHis-ePNP-GS-AHNP
NOTE: Values were determined from Lineweaver-Burk plots. Assays were conducted with variable concentrations of nucleoside substrates and fixed concentrations of phosphate and enzyme. Kinetic variables were determined from at least three independent studies, with each study done in triplicate. Staining at later times resulted in a strong signal only with propidium iodide. Association of CT26-HER-2/neu tumor cells with 1 Amol/L hDM-aH-AHNP resulted in apoptosis only in the presence of F-dAdo (Fig. 3) . Cells grow normally when only hDM-aH-AHNP or F-dAdo was present (Fig. 3) . When cells were examined for DNA fragmentation, DNA was completely degraded to small fragments ( Supplementary Fig. S4 ). 1 DNA fragmentation was seen only when both hDM-aH-AHNP and F-dAdo or F-Ade were present. When only hDMaH-AHNP or F-dAdo was added, only high molecular weight DNA was recovered (Supplementary Fig. S4 ).
1 In summary, the enzymatic activity of hDM or ePNP fused to AHNP is localized in the vicinity of HER-2/neu-expressing tumors, resulting in induction of apoptosis as a consequence of the conversion of F-dAdo to the cytotoxic drug, F-Ade.
Discussion
Cancer treatment using ADEPT has remained limited due to immunogenicity caused by the use of nonhuman components. Even with the administration of immunosuppressants such as cyclosporine, generation of antibodies against the bacterial enzyme and the murine targeting component has prevented continued therapy (6) . To address issues of immunogenicity, we have now shown that mutants of hPNP can use (deoxy)adenosine-based prodrugs as substrate. We focused on hPNP for two reasons: (a) the endogenous wild-type hPNP cannot use (deoxy)adenosine-based prodrugs as substrate and (b) multiple preclinical models have shown that the bacterial homologue of the enzyme is highly effective in cleaving (deoxy)adenosine-based prodrugs and generating high levels of cytotoxic drugs (11 -13, 15) . Among the mutations made within the purine binding pocket of the enzyme, hDM was most efficient in the phosphorolysis of F-dAdo. However, changing Asn 243 to Asp (hSM) was significant for the enzyme to use adenosine-based prodrugs as substrates probably due to hydrogen bond formation between Asp and 6-amino group and N7 of the purine (Supplementary  Fig. S5; ref. 10) . 1 Enzymatic efficiency of the hSM with adenosine-based prodrugs was further increased when the second mutation of Glu 201 to Gln was introduced. Crystal structures of hPNP in complex with either guanosine or inosine indicate that the N1-C2 side of these nucleotides faces Glu 201 of hPNP (8, 16, 22) . In fact, the COOH side chain of Glu 201 forms hydrogen bonds with the amino group at C2 in guanosine and with the N1 hydrogen of both guanosine and inosine (16, 18, 21) . Because the prodrugs contain highly electronegative fluorine or chlorine at the C2 position, replacing Glu 201 with glutamine should allow the amide group in Gln to form hydrogen bonds with the C2 fluorine (or C2 chlorine) and N1 of the prodrugs, which may enable the enzyme to accept the prodrugs with higher efficiency (Supplementary Fig. S5 ). 1 hDM is capable of using several (deoxy)adenosine-based prodrugs as substrate. Among the prodrugs tested, hDM had the highest kinetic efficiency with F-dAdo followed by F-Ado and Cl-dAdo, indicating that the hDM accepts (deoxy)adenosine prodrugs that contain fluorine more readily than those containing chorine. Fluorine is smaller than chlorine and may fit better in the nucleotide binding pocket of the enzyme. hDM had no activity with fludarabine, which contains arabinose as opposed to (deoxy)-ribose present in the other prodrugs tested. In general, PNPs favor ribonucleosides as substrates due to the stability of the oxocarbenium intermediate that forms on glycosidic bond breakage during nucleoside phosphorolysis Cells were stained with propidium iodide and Annexin V and examined by flow cytometry 60 h post-addition of hDM-aH-AHNP and F-dAdo. This study was repeated two independent times in duplicate. (11) . Even ePNP, which uses fludarabine as substrate, has 3,000-fold less activity with fludarabine than with F-dAdo (36) .
To target the enzymes to tumors, they were fused to AHNP. AHNP binds specifically to HER-2/neu on the cell surface (23, 30, 32, 37, 38) . Treatment of cells expressing HER-2/neu, but not the parental CT26 cells, with hDM-aH-AHNP or 6XHis-ePNP-GS-AHNP followed by washing and the addition of prodrug resulted in inhibition of cell proliferation (Fig. 2) . Although it has been shown that AHNP alone inhibits growth of HER-2/neu-expressing tumor cells such as SKBR3 or T6-17 in vitro and in vivo (23, 30, 31) , no growth inhibition of CT26-HER-2/neu was seen following treatment with hPNP-GS-AHNP (data not shown). Therefore, the observed cytotoxicity is due to conversion of prodrug to cytotoxic drug as a consequence of PNP enzymatic activity and is unrelated to AHNP function (39, 40) . Although proliferation of MCF-7-HER-2 cells is inhibited by anti-HER-2/neu antibodies, at the concentrations used, hDM-aH-AHNP had no affect by itself. However, at higher concentrations of hDM-aH-AHNP, the cytotoxicity generated as a consequence of prodrug conversion by the PNPs may combine with the antitumor activity of AHNP and result in greater inhibition of tumor growth.
hDM was fused to AHNP at its COOH terminus via two different linkers. The activity of hDM was increased when the rigid a-helical linker, instead of a flexible Gly 3 SerGly linker, was used to fuse the enzyme to AHNP. The rigid a-helical linker may result in a greater spatial separation of hDM from AHNP (33, 34) , thereby reducing unfavorable interactions between the two domains (enzyme and peptide) in the bifunctional hDM-aH-AHNP fusion protein. In addition, the rigidity of the a-helical linker would render the whole molecule less flexible and may make it less immunogenic than hDM-GS-AHNP (41, 42) .
The binding affinity of hDM-aH-AHNP for ECD HER-2 -Fc determined by surface plasmon resonance was found to be similar to the published binding affinity of the free peptide, AHNP, to ECD HER-2 -Fc (30) . Although the enzyme is a trimer, it remains unclear if more than one peptide on each trimer is accessible for binding simultaneously. Examination of the crystal structure of hPNP (Supplementary Fig. S6A ) 1 suggests that the COOH termini, where each AHNP is fused, point in different directions; hence, it may not be possible for the AHNPs in hDM-aH-AHNP to interact simultaneously with the immobilized ECD HER-2 . In contrast, 6XHis-ePNP-GS-AHNP interacted with ECD HER-2 -Fc with a f200-fold stronger affinity than hDM-aH-AHNP. The difference may reflect the different availability of multiple AHNP for simultaneous interaction within the two enzymes. 6XHis-ePNP-GS-AHNP is a hexamer consisting of a trimer of dimers. Within each dimer, the two COOH termini face in the same direction and are only 26 Å apart (Supplementary Fig. S6B ).
1 Additionally, the ePNP hexamer contains six AHNP peptides compared with the three present in hPNP. Moreover, different linkers connect the AHNP in the two proteins. With the flexible Gly 3 SerGly linker, it may be easier for multiple AHNP molecules to simultaneously bind the immobilized HER-2/neu.
When compared with the exceedingly efficient ePNP (6XHis-ePNP-GS-AHNP), hDM-aH-AHNP showed only a 36-fold reduced activity with F-dAdo as substrate (Table 2 ). Because it has been shown that expression of ePNP in only 0.1% to 1% of tumor cells results in complete eradication of tumors when prodrug is administered (13, 15) , the enzymatic activity of hDM-aH-AHNP should be sufficient to generate enough cytotoxic drug to result in complete tumor eradication. Importantly, we showed that conversion of F-dAdo to F-Ade due to enzymatic activity of hDM causes tumor cell apoptosis most probably due to inhibition of DNA, RNA, and protein synthesis (43) .
When compared with the currently leading therapeutics such as HER-2/neu-specific antibodies or small-molecule inhibitors, hDM-aH-AHNP-F-dAdo has multiple advantages. First, specific antibodies only target HER-2/neuexpressing cells. In contrast, the cytotoxic drug generated by hDM enzymatic activity freely diffuses through the cell membrane and causes apoptosis in the heterogeneous tumor mass irrespective of the cell surface expression of HER-2/neu (15) . Second, antibodies show variable efficacy in different patient groups possibly because of patientspecific differences such as Fc receptor polymorphism (44) . No such differences in patient responses would be expected with hDM-aH-AHNP-F-dAdo treatment. Finally, it has been shown that small-molecule inhibitor treatment results only in decreased cellular proliferation and, unlike hDM-aH-AHNP therapy, fails to induce tumor cell apoptosis (45) .
We have now shown that alteration of only two amino acids within hPNP is sufficient to produce an enzyme that uses (deoxy)adenosine-based prodrugs as substrate. Use of this mutant enzyme, which should be structurally similar to the naturally occurring human enzyme, is expected to result in greatly reduced immunogenicity in comparison with the currently used bacterial enzymes. We have shown that hDM fused to a peptide mimetic that binds HER-2/neu is targeted to HER-2/neu-expressing tumors. Moreover, fusion with other tumor-specific peptides, such as the peptide against prostate cancer cells (46), or with antibodies of different specificities should make it possible to target hDM to many different cancers. We anticipate that targeting hDM to tumors followed by administration of a prodrug will induce tumor cell apoptosis, with minimal systemic toxicity and immunogenicity.
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